Florida Cancer Specialists Pioneers Targeted Therapies for RAS Mutations at Global Symposium

Florida Cancer Specialists Pioneers Targeted Therapies for RAS Mutations



In a groundbreaking presentation at the 38th EORTC-NCI-AACR (ENA) Symposium held in Barcelona, Spain, Florida Cancer Specialists & Research Institute (FCS) showcased its leading-edge research on targeting RAS mutations. These mutations, particularly in the KRAS, NRAS, and HRAS genes, are known contributors to several difficult-to-treat cancers, including colorectal, lung, and pancreatic cancers.

Dr. Manish R. Patel, a prominent figure at FCS, emphasized the significance of targeting RAS mutations in advancing the next generation of cancer therapies during his elaborate presentation. He oversees the extensive drug development initiatives at FCS’s clinical trial units located in Sarasota and Central Florida, which are dedicated exclusively to Phase 1 clinical trials alongside the esteemed Sarah Cannon Research Institute (SCRI).

At the symposium, Dr. Patel co-authored an abstract titled A First-in-Human Phase 1/2 Study of SAR449336, an Oral Non-Covalent Pan-KRAS Inhibitor, in Patients With Advanced KRAS-Mutant Solid Tumors. This marks a significant step in clinical advancements aimed at treating cancers with KRAS mutations.

Moreover, Dr. Judy Wang, the Associate Director of Drug Development at FCS, presented pivotal findings from the ongoing clinical trials. One notable oral presentation covered the Preliminary Safety, Pharmacokinetics, and Efficacy of ERAS-0015 Results from the AURORAS-1 First-in-Human Trial. Additionally, she shared outcomes from the Preliminary Clinical Results of QTX3034, an Oral G12D-Preferring KRAS Inhibitor in Patients With KRASG12D-Mutated Endometrial Cancer.

Reflecting on the global collaboration in cancer research, Dr. Wang stated, "I am honored to present our research alongside global leaders in drug development and contribute to the scientific exchange that is advancing our understanding of cancer biology, emerging therapeutic targets, and new treatment approaches." Her remarks highlight the importance of community oncology in advancing cancer therapies available to patients.

FCS has also contributed to another pivotal abstract presented at the ENA 2026, which details the preliminary phase 1 results from the AVENTINE-1 study—a phase 1/2 study on ACZO-1418, an EGFR-HER3 bispecific antibody-drug conjugate designed for patients with locally advanced or metastatic solid tumors.

Partnerships with renowned entities like Sarah Cannon Research Institute have bolstered FCS’s capabilities, enabling them to conduct nearly 180 active clinical trials annually across nearly 30 locations statewide. These trials play a crucial role in enhancing patient care by providing early access to innovative therapies, a characteristic that places FCS at the forefront of oncology research.

Throughout its 40-year legacy, FCS’s commitment to clinical research has positioned it as a leader in the market, offering patients access to groundbreaking treatments well before FDA approval. The institute’s highly trained physicians are steadfastly dedicated to developing personalized treatment plans leveraging advancements in precision oncology to optimize patient outcomes.

In conclusion, Florida Cancer Specialists & Research Institute not only embodies the forefront of cancer treatment innovations but also emphasizes the essential role it plays in redefining cancer care through research and new therapy access for patients. Their continuous efforts ensure that advanced cancer therapies are not just a future promise but a present reality for many individuals fighting against cancer.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.